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Background: The purpose of this study is the investigation of the effects of intrathecally injected
dexmedetomidine and methylprednisolone and their dominancy over one another in rats with generated
Spinal Cord Injury (SCI).
Methods: 40, female, adult Wistar Albino rats weighing 220e260 g were included in the study. The rats
were ﬁxed with Intrathecal catheter (IT) and divided into four groups. All subjects were applied T7e10
laminectomy after catheter. Group S (n:10) was injected with IT 10 mL isotonic saline; Group C (n:10) with
IT 10 mL isotonic saline after SCI; Group D (n:10) with IT one doze 10 mL of dexmedetomidine after SCI;
Group M (n:10) IT one dose 10 mL of methylprednisolone. The subjects were sacriﬁced 72 h after this
operation. The damaged area was removed biochemically and histopathologically examined.
Results: Antioxidant and inﬂammatory parameters searched for in all damages tissue were statistically
different in all groups from group S. They were different in group M and group D than group C
(p < 0.001). After the comparison of group D and group M, PON and IL6 values were higher in group D
(p ¼ 0.003, p ¼ 0.035) while the other two biochemical parameters were similar in both groups (Table 1).
After histopathologic trials, edemas, bleeding and necrosis were found less in group S while at the most
in group C (p < 0.001). In group M and group D, however, they were higher than group S and lower than
group C (p < 0.001). After the comparison of group D and group M, while there was no difference in
terms of edema necrosis, the amount of bleeding was lower in group D (p < 0.001) (Table 2).
Conclusions: It has been discovered that intrathecal use of dexmedetomidine caused neuroprotective
effects similar to methylprednisolone.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
During the acute phase of the spinal cord injury, many degen-
erative mechanisms cause secondary damage to nerve tissue.1
Irreversible paralysis caused by spinal cord injury (SCI) has been
recognized and looked into for a neurobiological explanation for
over a century.2 To that end, many experimental methods such asof Medicine, Anesthesiology
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ciates Ltd. Published by Elsevier Ltlaceration,3 impact,4 clip5 (compression) and secondary spinal
dislocation6 were employed. Through these experimental models,
explanation of pathophysiological processes originating post-SCI is
targeted and neuroprotective treatment methods are being
improved.7 Not only voluntary engine, sensorial, urologic and
sexual functions but also inspiratory, cardiovascular, gastrointes-
tinal and muscleeskeleton systems are affected from SCIs as well.8
This causes many endogen neuroprotective compounds to be
released and recovery response to begin.1,9
Among many pharmacologic agent examined for this subject
matter, methylprednisolone was declared the standard treatment
option accepted for acute SCI and the investigations in this
subject continue.10 In a new study where SCI was experimentally
generated in rats, the neuroprotective activity of the use of
intraperitoneal dexmedetomidine (DEX) was shown equal tod. All rights reserved.
Table 1
The biochemical values of the groups in tissue.
Group S Group C Group D Group M
PON 153.35  22.45 86.65  18.95a 121.66  20.77a,b,c 91.89  11.67a
TAS 0.40  0.05 0.03  0.03a 0.30  0.86a,b 0.28  0.07a,b
TOS 75.92  16.23 122.85  40.47a 72.23  24.54b 86.76  16.07a
MDA 1.85  0.41 3.07  0.73a 1.84  0.24b 2.19  0.96b
SOD 5.30  1.04 8.47  2.42a 5.10  1.49b 5.86  1.08b
NO 0.15  0.35 0.25  0.64a 0.15  0.23b 0.18  0.08b
IL6 1.66  0.21 2.82  0.46a 1.44  0.37b,c 1.08  0.26a,b
TNF-a 10.45  1.16 10.83  1.92 9.26  0.77a 8.68  0.59a,b
S ¼ sham, C ¼ control, D ¼ dexmedetomidine, M ¼ methylprednisolone.
PON ¼ paraoxonase, TAS ¼ total antioxidant status, TOS ¼ total oxidative status,
MDA ¼ malonyldialdehyde, SOD ¼ superoxide dismutase, NO ¼ nitrous oxide,
IL6 ¼ interleukin 6, TNF-a ¼ tumor necrosis factor-a.
a Different from S group (p < 0.001).
b Different from C group (p < 0.01).
c Different from M group (p < 0.001).
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tecal use of methylprednisolone and DEX for neuroprotective pur-
poses appeared during the literature search. In this study our target
was investigate their affects with lower doses and their dominance
over one another in order to decrease the systematic side effects of
these two drugs.
2. Methods
2.1. Animals
Ethical approval for this study (Ethical Committee protocol number 1) was
provided by the Animal Trials Ethical Committee of Dicle University Hospitals,
Diyarbakir, Turkey (Chairperson Prof MS Kemaloglu) on 27 October 2010. Forty
adult, female Wistar Albino rats with normal engine activity weighting 220e260 g
were included in the study. Standard laboratory conditions (illuminating 12 h daye
12 h night, room temperature 22e22 C) were provided for the subjects and the rats
were fed with ad-libitum.
2.2. Intrathecal catheters
All rats were injected intraperitoneal 80 mg/kg ketamine (Ketalar, ParkeDavis-
Eczacıbas¸ı, _Istanbul, Türkiye) and put under in order to preserve the rats’ sponta-
neous respiration. The subjects were put on the table face down. The 4  2 cm area
reaching for the caudal between the two ears were shaved andwipedwith povidone
iodine local anesthesia was introduced to the incision point with 1% lidocaine. A
2 cmmiddle line incisionwas made on the caudal between the two ears on the skull
and surﬁcial neck muscles were slowly pulled using a retracted with an incline from
the top of the head to the caudal. The sub muscles were divided in the middle line
and then occipital bulges of the muscles were ﬁxed 0.5 cm from both sides of the
middle line from its footholds. At this point, the facial layer at the back of the skull
was retracked and ﬁrst vertebral connection of the occipital bone was revealed.
Approximately 2e3 mm of cartilage tissue at the top of the spinal bulge of the
axis was retracted via penset and a clear sighting of atlantoaxial membran was
achieved. In order not to damage the medulla spinal in the middle section of the
atlantoaxial membra, a small hole was drilled with the pointy tip of the 21 G needle
and a leakage of the brains spinal ﬂuid was observed. Polyethylene catheter (P.E.; i.d.
0.28 mm ve o.d. 061 mm, Becton Dickinson, Philadelphia, USA) was intrathecally
pushed 4 cm into the caudal, its part staying outside was burned and sealed. Incision
ﬁeld was closed to anatomic ﬂoors appropriately and catheter was identiﬁed and the
surgical procedure was terminated.12,13 The rats that did not experience engine
functionality disorder in their front or rear legs after the procedure, were injected
200 mg 2% lidocaine. In 30 s after the injection, paralysis and dragging behavior were
observed in the rear legs of the subjects and intrathecal plantation of catheter was
conﬁrmed.
2.3. Creation of SCI
All rats were injected intraperitoneal 80 mb/kg ketamine and put under in order
to preserve the rats’ spontaneous respiration 24 h after the catheter plantation. A
3  2 cm area on the back was shaved, local antisepsis was applied with povidone
iodine, muscles past the T5e12 level skin, sub-skin tissue and paravertebral muscles
was sliced laterally sliced with obtuse dissection and T7e10 lamina was visible. A
level total laminectomy was applied while paying attention so as not to damage the
dura-matter. Rats other than the group S clipped (Aesculap FE 721 K) for 1 min via
Yasargil aneurysm with a 63 g force around the dura and spinal cord. Following
hemostasis, incision ﬁeld was closed with 3/0 silk. Drug and saline applications of
the groups, using the intrathecal catheter Hamilton injector (Hamilton Bonaduz AG,
Bonaduz, Swiss); Group S (n:10) was given 10 mL isotonic saline after only lam-
inectomy. Group C (n:10) was given intrathecal 10 mL isotonic saline after the SCI was
generated. Group D (n:10) was intrathecally given one döse of 10 mL (1 mg/kg) DEX
after SCI was generated. Group M (n:10) was intrathecally given one dose of 10 mL
(3 mg/kg) methylprednisolone after SCI was generated. Catheter was cleansed with
5 mL saline after the drug administration. The subjects were sacriﬁced after taking
intracardiac blood samples up to 72 h the spinal trauma was generated. Injury area
was carefully dissected and a spinal cord sample of 2 cm with the traumatized area
at the center. A T8 level rostal tissue sample of 1 cm from each rat was taken for
biochemical analysis and caudal 1 cm tissue sample was taken for pathologic
examination.
2.4. Biochemical analysis
The excised tissue samples were weighed, immediately stored at70 C. Tissues
minced, then homogenized in ﬁve volumes (w/v) of phosphate buffer Assays were
performed on the supernatant of the homogenate that is prepared at 14.000 rpm for
30min atþ4 C.14 Total antioxidant capacity and total oxidant status were measured
by Erel’s methods,15,16 Malonyldialdehyde (MDA) content were measuredspectrophotometrically as described previously.17 Serum PON1 levels were
measured spectrophotometrically by modiﬁed Eckerson method, Initial rates of
hydrolysis of paraoxon (0.0-diethyl-0-p-nitrophenylphosphate; Sigma Chemical Co.
London, UK) were determined by measuring liberated-p-nitrophenol at 405 nm at
37 C.18 The plasma NO, SOD (Cayman Chemicals, Ann Arbor, MI, USA), IL6 and TNF
alpha (Bender Med Systems, Vienna, Austria) levels were determined using the
enzyme-linked immunosorbent assay method.2.5. Histopathological analysis
For histopathological investigation, spinal cord samples were ﬁxed in 10%
formalin for 24 h and after routine histological preparation, the tissue samples were
embedded in parafﬁn and horizontally sectioned into 5 mm slices with a microtome.
After deparafﬁnization, sections were mounted on slides and stained with hema-
toxylin and eosin (H&E). Randomly selected ten microscopic ﬁelds from gray matter
were examined by a pathologist blinded to the study groups. The slides were
assessed under a light microscope (at 100 magniﬁcation) for edema, hemorrhage
and necrosis (Scoring: Edema (absent; 0, mild; 1, moderate; 2, severe; 3)), Hemor-
rhage (absent; 0, one focus or two foci; 1, more than two foci; 2, severe; 3) Necrosis
(absent; 0, focal necrobiosis; 1, focal necrosis; 2, severe necrosis; 3).2.6. Statistical analysis
Statistical analysis was performed by SPSS for Windows 13.0 (SPSS Inc., Chicago,
IL, USA). Data were presented as mean values  standard deviation for biochemical
values. Groups were compared by using the nonparametric KruskaleWallis test.
ManneWhitney U test was used for binary comparisons. p values of less than 0.05
were considered signiﬁcant.3. Results
3.1. Biochemical results
Antioxidant and inﬂammatory parameters searched for in all tis-
sue samples were statistically different in all groups from group S.
Theywere different in GroupMand group D than group C (p< 0.001).
After the comparison of group D and group M, PON and IL6 values
were higher in group D (p ¼ 0.003, p ¼ 0.035) while the other two
biochemical parameters were similar in both groups (Table 1).3.2. Histopathologic results
After histopathologic trials, edemas, bleeding and necrosis in
medulla spinalist were found less in group S while at the most in
group C (p < 0.001). In groups M and D, however, edemas, bleeding
and necrosis was observed to be more than group S and less than
group C (p < 0.001). After the comparison of group D and group M,
while there was no difference in terms of edema necrosis, the
amount of bleeding was lower in group D (p < 0.001) (Table 2)
(Figs. 1e4).
Table 2
The histopathological evaluation scores of the groups.
Parameters Group S Group C Group D Group M p
Eudema 0.70  0.68 2.60  0.52a 1.30  0.48a,b 1.70  0.48a,b <0.001
Bleeding 0.00  0.00 2.00  0.67a 1.10  0.88a,b 1.90  0.74a,c <0.001
Necrosis 0.00  0.00 1.80  0.63a 1.00  0.47a,b 1.00  0.00a,b <0.001
S ¼ Sham, C ¼ Control, D ¼ Dexmedetomidine, M ¼ Methylprednisolone.
a Different from S group (p < 0.001).
b Different from C group (p < 0.01).
c Different from C group (p < 0.001).
Fig. 2. Control group. Severe hemorrhage and necrosis in the spinal cord (H&E
stain, 100).
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After the damage of the spinal cord injury in acute phase,
integrity of blood vessels and barrier of bloodebrain was damages
and a rapid surge of neutrophil to the injured area is observed.19
Ischemic situation originating from this process triggers a patho-
physiologic loop than ends with neural death by causing secondary
damage. At the ﬁrst phase of this loop, the lactic acid accumulated
as a result of the anaerobic glucose cause edemas with the increase
of membrane’s permeableness. In the second phase, excitatory
neurotransmitters are released and voltage contingent Naþ and
Caþþ channels are opened. It activates the enzymes that increase oil
acids free in cells such as calcium lipid peroxidase, protease and
phospholipase and free oxygen and nitrogen radicals. Free oxygen
radicals cause oxidative stress and degeneration of cell membranes
and programmed cell death following it.11
Even though many pharmacologic agents were tried in spinal
cord injuries, none of them, except for methylprednisolone, made it
to clinic use.20,21 Lately, neuroprotective activity and routine use of
methylprednisolone in SCIs has been questioned. According to
NASCIS 2 study, administration of methylprednisolone in 8 h
following the SCI is effective.22 Additionally, the results of this study
have been conﬁrmedwith studies following it.10,23,24 Because of the
complications of steroid use, the American Association of Neuro-
logical Surgeons and the Congress of Neurological Surgeons do not
recommend it unless its ﬁnal contributions surpasses its side
effects.
DEX, a potent a2-adrenergic agonist, is being more common.25
The studies have shown DEX’s neuroprotective efﬁciency by
inhibiting its cortical apoptosis. Neuroprotective activity inhibits
the release of catecholamine by activating presynaptic a2-
adrenergic receptors. Therefore, cell death is prevented by
decreasing ischemic damage and vasospasm.26,27 Dexmedetomi-
dine contributes to spinal perfusion by activating a2-adrenerjik
receptors, inhibiting the release of catecholamine and reducing
vasospasm.26e29
However, there studies that indicate DEX has no neuro-
protective effects.28 It has been stated that DEX prevents neural
death by providing maximal inhibition at intraperitoneal doses of
3e6.5 mg/kg.26,30,31 It has been shown that DEX can safely be usedFig. 1. Sham group. Normal histomorphology in the spinal cord (H&E stain, 100).intrathecally at doses of 1 mg/kg.32 We, too, have intrathecally used
DEX at a doze of mg/kg in this study.
In the English literature, no information source was seen in the
practicing time in which dexmedetomidine produces maximum
effect. In our study, we preferred to use dexmedetomidine and
metilprednizolon in ﬁrst 8 h synchronously.
Oxidant and antioxidant systems of the organism are balanced.
When this balance is disrupted in favor of oxidants, leucocytes
produce inﬂammatory mediators and free oxygen radicals. Which
cause damage on the cell level.33 It has been shown in studies that
PON, an antioxidant enzyme, can be used for following up on the
antioxidant system after spinal cord injuries.34 It has been discov-
ered that intraperitoneal dexmedetomidine35 and methylprednis-
olone increase PON levels.11 We have discovered in our study that
intrathecal dexmedetomidine and methylprednisolone increases
PON levels substantially. This increase was more vivid in dexme-
detomidine group (Table 1).
TAS and TOS levels of the parameters examined in our study
were statistically and substantially low in our study groups in
comparison to group C. TAS is the total of enzymatic (glutathione,
peroxidase, catalase, SOD, etc.) and non-enzymatic (vitamins, C, E,
melatonin, albumin, etc.) antioxidants and TOS is the total of oxi-
dants. TAS is the basic defence mechanism against the oxidative
distress in the body. For example, superoxide radicals produced
with oxidative distress are turned into hydrogen peroxide (H2O2)
by SOD enzyme. H2O2 is not a radical; however, it has the potential
to create radicals. It accesses tissues and organs remote from its
point of origin and settles in through the cell membrane. If there are
transitional metals in where H2O2 has reached, it poses as an
important source for the production of the hydroxy radical which is
even more dangerous than superoxide radicals via Fenton reaction.
This results in the increase of oxidative distress.36,37 However, the
MDA level which was a marker of oxidative distress in our study
was substantially lower in all groups when compared to Group C.
These results demonstrate that dexmedetomidine and methyl-
prednisolone prevent possible oxidative distress. It is stated in the
literature that MDA levels of intraperitoneal dexmedetomidine and
methylprednisolone decrease in SCI.11Fig. 3. Methylprednisolone group. Mild to moderate hemorrhage and some necrosis
foci in the spinal cord (H&E stain, 100).
Fig. 4. Dexmedetomidine group. Mild hemorrhage in the spinal cord (H&E stain,100).
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was statistically and substantially lower in study groups. NO is a
molecule with oxidant and antioxidant properties, acting as a
double sided blade. When the inducible nitric oxide is over pro-
duced by synthase, it causes oxidative stress to increase with its
oxidant properties. The data from our study indicate that dexme-
detomidine and methylprednisolone injected to the rats decreased
NO production and had antioxidant effects.36,37
The enzyme with the fastest respond rate to inﬂammation in-
crease is SOD. This response usually shows itself in the way of a
decrease in SOD values. Aslan and his colleague37 have discovered
that SOD levels decreased in studies they used dexmedetomidine.
In our study, SOD values decreased in both dexmedetomidine and
methylprednisolone groups. The reason of this decrease might be
over consumption against oxidative distress.
TNF-a and IL6 are preinﬂammatory stockings increasing in
spinal cord injuries and are related to cell death and inﬂammation
rate.39 Can and his colleagues has declared that tissue TNF-a and
IL6 levels were substantially lower in the post-SCI groups they used
dexmedetomidine and methylprednisolone than the control
group.19 We, too, have found the TNF-a and IL6 levels to be sub-
stantially lower in dexmedetomidine and methylprednisolone
groups. However, while Can and colleagues did not ﬁnd any dif-
ference between the two drugs, we have found the IL6 levels to be
lower in methylprednisolone group in our study.
It is stated in the literature that dexmedetomidine and meth-
ylprednisolone decreases necrosis and ischemic areas.11,19,30,38 We
too have observed that dexmedetomidine and methylprednisolone
substantially decreased, bleeding, edema and necrosis areas
compared to the control group, in the histopathologic evaluations
of our study. When compared, we have observed that dexmede-
tomidine decreased bleeding and edemas more than methylpred-
nisolone and that necrosis were similar in the two groups (Table 2).
There are some limitations in our study. Firstly, comparison of
different steroids as well as comparisons of mode of therapy was
not evaluated in our study. Secondly, comparison of
medications’ Peritoneal/IV/Intrathecal administration for inﬂam-
matory, histopathological and adverse reactions was not planned.
Also, we did not evaluate subgroup results and interpretation of
inﬂammatory mediators.
More researches are needed for whether the effect of dexme-
detomidine and methylprednisolone is comparable to intravenous
injection as compared to intrathecal injection.
5. Conclusion
In conclusion; Dexmedetomidine can be seen as an agent than
can be safely used instead of methylprednisolone induced via
intrathecal ways. Further studies are necessary in this subject
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